Pyxis Oncology to Focus on PYX-201, Suspends PYX-106 Program

Dow Jones2024-12-20

By Stephen Nakrosis

Pyxis Oncology said Thursday it will focus resources on its lead asset, PYX-201, which is being studied as a treatment for certain patients with head and neck squamous cell carcinoma, with additional potential in other solid tumors.

The company also said it decided to suspend further clinical investment in PYX-106, which was being studied in a Phase 1 monotherapy trial of patients with advanced solid tumors.

Pyxis said PYX-201 showed significant response evaluation criteria in solid tumors, or Recist, responses in head and neck squamous cell carcinoma. In November, the company said it reported positive preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating the treatment's safety and efficacy in multiple solid tumor types.

The portfolio prioritization supports a development plan for PYX-201 in several dose expansion studies, both as monotherapy and in combination, the company added.

Pyxis said its current cash position is expected to fund its planned trials of PYX-201 into the second half of 2026.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

December 19, 2024 17:06 ET (22:06 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492848050?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 06:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492848050","market":"sg","top_or_hot":-1,"title":"Pyxis Oncology to Focus on PYX-201, Suspends PYX-106 Program","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Pyxis Oncology said Thursday it will focus resources on its lead asset, PYX-201, which is being studied as a treatment for certain patients with head and neck squamous cell carcinoma, with additional potential in other solid tumors. \n</p>\n<p>\n  The company also said it decided to suspend further clinical investment in PYX-106, which was being studied in a Phase 1 monotherapy trial of patients with advanced solid tumors. \n</p>\n<p>\n  Pyxis said PYX-201 showed significant response evaluation criteria in solid tumors, or Recist, responses in head and neck squamous cell carcinoma. In November, the company said it reported positive preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating the treatment's safety and efficacy in multiple solid tumor types. \n</p>\n<p>\n  The portfolio prioritization supports a development plan for PYX-201 in several dose expansion studies, both as monotherapy and in combination, the company added. \n</p>\n<p>\n  Pyxis said its current cash position is expected to fund its planned trials of PYX-201 into the second half of 2026. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 19, 2024 17:06 ET (22:06 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pyxis Oncology to Focus on PYX-201, Suspends PYX-106 Program</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPyxis Oncology to Focus on PYX-201, Suspends PYX-106 Program\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 06:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Stephen Nakrosis \n\n\n \n\n\n  Pyxis Oncology said Thursday it will focus resources on its lead asset, PYX-201, which is being studied as a treatment for certain patients with head and neck squamous ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PYXS","symbol_name":"Pyxis Oncology, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492848050","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492848050","pubTimestamp":1734645960,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Pyxis Oncology said Thursday it will focus resources on its lead asset, PYX-201, which is being studied as a treatment for certain patients with head and neck squamous cell carcinoma, with additional potential in other solid tumors.The company also said it decided to suspend further clinical investment in PYX-106, which was being studied in a Phase 1 monotherapy trial of patients with advanced solid tumors.Pyxis said PYX-201 showed significant response evaluation criteria in solid tumors, or Recist, responses in head and neck squamous cell carcinoma. In November, the company said it reported positive preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating the treatment's safety and efficacy in multiple solid tumor types.The portfolio prioritization supports a development plan for PYX-201 in several dose expansion studies, both as monotherapy and in combination, the company added.Pyxis said its current cash position is expected to fund its planned trials o","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PYXS":"Pyxis Oncology, Inc.","BK4139":"生物科技"},"translate_title":"Pyxis Oncology将专注于PYX-201，暂停PYX-106项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PYXS":1},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Pyxis Oncology said Thursday it will focus resources on its lead asset, PYX-201, which is being studied as a treatment for certain patients with head and neck squamous cell carcinoma, with additional potential in other solid tumors. \n\n\n  The company also said it decided to suspend further clinical investment in PYX-106, which was being studied in a Phase 1 monotherapy trial of patients with advanced solid tumors. \n\n\n  Pyxis said PYX-201 showed significant response evaluation criteria in solid tumors, or Recist, responses in head and neck squamous cell carcinoma. In November, the company said it reported positive preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating the treatment's safety and efficacy in multiple solid tumor types. \n\n\n  The portfolio prioritization supports a development plan for PYX-201 in several dose expansion studies, both as monotherapy and in combination, the company added. \n\n\n  Pyxis said its current cash position is expected to fund its planned trials of PYX-201 into the second half of 2026. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 19, 2024 17:06 ET (22:06 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492848050"}